17 completed, 5 terminated, 2 withdrawn. 24 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 17, Terminated 5, Withdrawn 2 |
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow tanespimycin: new trials by email Literature Review of tanespimycin trials Research Report on tanespimycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer IPI-504, Everolimus - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 47 | 2011-07-01 | 2014-11-13 |
| A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer IPI 504 plus Docetaxel, Placebo plus Docetaxel - Non Small Cell Lung Cancer | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 226 | 2011-05-01 | 2014-05-19 |
| IPI-504 in NSCLC Patients With ALK Translocations IPI-504 - Lung Cancer, Stage IIIb Lung Cancer | Phase 2 | Terminated | Massachusetts General Hospital | 3 | 2010-10-01 | 2017-12-04 |
| Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma IPI-504 - Dedifferentiated Liposarcoma | Phase 2 | Withdrawn | Infinity Pharmaceuticals, Inc. | 2010-01-01 | 2015-04-14 | |
| Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer IPI-504, Trastuzumab - Breast Cancer, HER2 Positive Breast Cancer | Phase 2 | Terminated | Infinity Pharmaceuticals, Inc. | 29 | 2009-03-01 | 2012-12-11 |
| A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer IPI-504 - Breast Cancer | Phase 1 / Phase 2 | Withdrawn | MedImmune LLC | 56 | 2008-04-01 | 2010-02-03 |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer gemcitabine hydrochloride, tanespimycin - Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2008-03-01 | 2014-07-25 |
| A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma IPI-504 - Metastatic Melanoma | Phase 2 | Terminated | Infinity Pharmaceuticals, Inc. | 1 | 2008-02-01 | 2012-12-10 |
| A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer IPI-504 - Prostate Cancer, Prostatic Neoplasms | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 19 | 2007-11-01 | 2012-12-11 |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer gemcitabine hydrochloride, tanespimycin - Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 29 | 2007-10-01 | 2014-05-20 |
| A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma tanespimycin, Bortezomib - Multiple Myeloma | Phase 2 / Phase 3 | Completed | Bristol-Myers Squibb | 22 | 2007-08-01 | 2015-12-07 |
| Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) IPI-504 - Lung Cancer | Phase 1 / Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 88 | 2007-01-01 | 2012-12-10 |
| Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin Tanespimycin - Advanced Malignancies | Phase 2 | Completed | Bristol-Myers Squibb | 6 | 2006-07-01 | 2015-10-12 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis tanespimycin - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 37 | 2006-05-01 | 2012-03-15 |
| Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin Tanespimycin - Solid Tumors, Breast Cancer | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 25 | 2005-12-01 | 2015-11-04 |
| Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer tanespimycin, laboratory biomarker analysis - Recurrent Breast Cancer, Stage IIIB Breast Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 11 | 2005-09-01 | 2017-01-16 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma tanespimycin - Melanoma (Skin) | Phase 2 | Completed | Cancer Research UK | 25 | 2005-03-01 | 2013-06-26 |
| 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma tanespimycin - Anaplastic Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2005-02-01 | 2014-05-30 |
| 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy tanespimycin, laboratory biomarker analysis - Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2005-01-01 | 2017-04-18 |
| Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer tanespimycin - Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2004-12-01 | 2017-02-15 |
Showing 20 of 24. Sign in to see all of them.
Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (3) · Melanoma (3) · Carcinoma, Renal Cell (2) · Hodgkin Disease (2) · Kidney Neoplasms (2) · Lymphoma, Mantle-Cell (2) · Prostatic Neoplasms (2) · Adenocarcinoma, Follicular (1) · Angiolymphoid Hyperplasia with Eosinophilia (1) · Burkitt Lymphoma (1) · Carcinoma, Large Cell (1) · Carcinoma, Medullary (1) · Carcinoma, Ovarian Epithelial (1)
National Cancer Institute (NCI) (9) · Infinity Pharmaceuticals, Inc. (7) · Bristol-Myers Squibb (3) · Cancer Research UK (1) · Massachusetts General Hospital (1) · MedImmune LLC (1) · Memorial Sloan Kettering Cancer Center (1) · National Institutes of Health Clinical Center (CC) (1)
United States (23) · Hungary (1) · Romania (1) · Russia (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Anas Younes (1) · Antonio T. Fojo, MD, PhD (1) · David E. Weng, M.D., PhD (1) · Elaina Gartner (1) · Elisabeth Heath (1) · Gnanamba V. Kondagunta, MD (1) · Jeffrey Moley (1) · Lecia Sequist, MD (1) · Lecia V. Sequist, MD, MPH (1) · Nancy Bartlett (1) · Paul Chapman (1) · Paul Haluska (1) · Pedro Santabarbara, M.D. (1) · Pedro Santabarbara, MD (1)
N01CM62205 (3), P30CA015083 (2), N01CM17104 (1), N01CM62206 (1), N01CM62207 (1), P30CA016672 (1), R21CA117070 (1), U01CA062487 (1), U01CA062502 (1), U10CA031946 (1)